TC
CRSP icon

TwinBeech Capital’s CRISPR Therapeutics CRSP Stock Holding History

TwinBeech Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,072
Closed -$214K – 619
2025
Q4 		$214K Buy
+4,072
New +$244K 0.02% 530
2025
Q2 		– Sell
-31,578
Closed -$1.07M – 701
2025
Q1 		$1.07M Buy
+31,578
New +$1.34M 0.02% 476
2024
Q3 		– Sell
-146,473
Closed -$7.91M – 710
2024
Q2 		$7.91M Buy
+146,473
New +$8.47M 0.16% 170
2022
Q3 		– Sell
-37,247
Closed -$2.26M – 655
2022
Q2 		$2.26M Buy
+37,247
New +$2.19M 0.1% 203
2020
Q2 		– Sell
-7,412
Closed -$314K – 382
2020
Q1 		$314K Buy
+7,412
New +$383K 0.13% 220

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return